Literature DB >> 11831553

Cannabinoids and neuroprotection.

R I Grundy1, M Rabuffetti, M Beltramo.   

Abstract

Cannabinoid compounds are endowed with pharmacological properties that make them interesting candidates for therapeutic development. These properties have been known since antiquity. However, in the last decade extremely important advances in the understanding of the physiology, pharmacology, and molecular biology of the cannabinoid system have given this field of research fresh impetus and have renewed the interest in the possible clinical exploitation of these compounds. In the present review we summarize the effects elicited, at the cellular level, by cannabinoids acting through receptor-dependent and receptor-independent mechanisms. These data suggest different ways by which cannabinoids may act as neuroprotective agents (prevention of excitotoxicity by inhibition of glutamate release, antioxidant effects, anti-inflammatory actions, etc.). The experimental evidence supporting these hypotheses are presented and discussed with regard to both preclinical and clinical studies in disease states such as cerebral ischemia, brain trauma, and Multiple Sclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11831553     DOI: 10.1385/MN:24:1-3:029

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  188 in total

1.  HU-211, a non-psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture.

Authors:  N Eshhar; S Striem; A Biegon
Journal:  Neuroreport       Date:  1993-12-13       Impact factor: 1.837

2.  Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice.

Authors:  M Kathmann; B Weber; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-01       Impact factor: 3.000

Review 3.  Cardiovascular effects of endocannabinoids--the plot thickens.

Authors:  G Kunos; Z Járai; K Varga; J Liu; L Wang; J A Wagner
Journal:  Prostaglandins Other Lipid Mediat       Date:  2000-04       Impact factor: 3.072

4.  Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.

Authors:  A J Hampson; L M Bornheim; M Scanziani; C S Yost; A T Gray; B M Hansen; D J Leonoudakis; P E Bickler
Journal:  J Neurochem       Date:  1998-02       Impact factor: 5.372

5.  Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor.

Authors:  A C Howlett; T M Champion; G H Wilken; R Mechoulam
Journal:  Neuropharmacology       Date:  1990-02       Impact factor: 5.250

6.  Protein kinase-dependent phosphorylation and cannabinoid receptor modulation of potassium A current (IA) in cultured rat hippocampal neurons.

Authors:  J Mu; S Y Zhuang; R E Hampson; S A Deadwyler
Journal:  Pflugers Arch       Date:  2000-03       Impact factor: 3.657

7.  Enantiomeric cannabinoids: stereospecificity of psychotropic activity.

Authors:  R Mechoulam; J J Feigenbaum; N Lander; M Segal; T U Järbe; A J Hiltunen; P Consroe
Journal:  Experientia       Date:  1988-09-15

8.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

9.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.

Authors:  C C Felder; K E Joyce; E M Briley; J Mansouri; K Mackie; O Blond; Y Lai; A L Ma; R L Mitchell
Journal:  Mol Pharmacol       Date:  1995-09       Impact factor: 4.436

10.  Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; J W Huffman; L Layward
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

View more
  14 in total

1.  A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis.

Authors:  Cristina Benito; Woong-Ki Kim; Wong-Ki Kim; Iván Chavarría; Ceceila J Hillard; Ken Mackie; Rosa M Tolón; Kenneth Williams; Ken Williams; Julián Romero
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

2.  Cannabinoid Receptor Type 1 Agonist ACEA Protects Neurons from Death and Attenuates Endoplasmic Reticulum Stress-Related Apoptotic Pathway Signaling.

Authors:  Talita A Vrechi; Fernanda Crunfli; Andressa P Costa; Andréa S Torrão
Journal:  Neurotox Res       Date:  2017-11-13       Impact factor: 3.911

3.  Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model.

Authors:  Ming Zhang; Billy R Martin; Martin W Adler; Raj K Razdan; Jack I Jallo; Ronald F Tuma
Journal:  J Cereb Blood Flow Metab       Date:  2007-01-24       Impact factor: 6.200

Review 4.  Acute neuronal injury, excitotoxicity, and the endocannabinoid system.

Authors:  Mario van der Stelt; Wouter B Veldhuis; Mauro Maccarrone; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Vincenzo Di Marzo; Johannes F G Vliegenthart
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

5.  The cannabinoid WIN 55212-2 mitigates apoptosis and mitochondrial dysfunction after hypoxia ischemia.

Authors:  D Alonso-Alconada; A Alvarez; F J Alvarez; J A Martínez-Orgado; E Hilario
Journal:  Neurochem Res       Date:  2011-09-11       Impact factor: 3.996

6.  Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging.

Authors:  Onder Albayram; Judith Alferink; Julika Pitsch; Anastasia Piyanova; Kim Neitzert; Karola Poppensieker; Daniela Mauer; Kerstin Michel; Anne Legler; Albert Becker; Krisztina Monory; Beat Lutz; Andreas Zimmer; Andras Bilkei-Gorzo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

Review 7.  Cannabinoid as a neuroprotective strategy in perinatal hypoxic-ischemic injury.

Authors:  Daniel Alonso-Alconada; Antonia Alvarez; Enrique Hilario
Journal:  Neurosci Bull       Date:  2011-08       Impact factor: 5.203

Review 8.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury.

Authors:  M Zhang; B R Martin; M W Adler; R K Razdan; D Ganea; R F Tuma
Journal:  Neuroscience       Date:  2008-01-25       Impact factor: 3.590

Review 10.  Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.

Authors:  A C Parrott; R M Milani; E Gouzoulis-Mayfrank; J Daumann
Journal:  J Neural Transm (Vienna)       Date:  2007-05-24       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.